© Reuters. FILE PHOTO: Signs and age groups are shown for the Pfizer and Moderna vaccines at a vaccination center as California opens vaccine eligibility to residents 16 and older during the coronavirus disease (COVID-19) outbreak in Chula Vista, California
COVID-19 vaccine from AstraZeneca (NASDAQ 🙂 combined with a second dose from Pfizer-BioNTech or Modern (NASDAQ:) s sting offers "good protection," Denmark's State Serum Institute said on Monday.
A growing number of countries are considering switching to other second-dose COVID-19 vaccines, a measure that is particularly necessary in Denmark after health authorities stopped vaccination with AstraZeneca's vaccine in April due to rare side effects.
More than 144,000 Danes, mostly health frontline workers and the elderly, received their first vaccination with AstraZeneca's vaccine but were subsequently vaccinated with either Pfizer-BioNTech or Moderna.
"The study shows that 14 days after a combined vaccination program, the risk of infection with SARS-CoV-2 is reduced by 88% compared to unvaccinated people," said the State Serum Institute (SSI).
This is "high efficacy," added SSI, comparable to the 90% efficacy rate of two doses of Pfizer-BioNTech's vaccine, which was confirmed in another Danish study.
The study published last week spanned more than five months between February and June of this year, a period when the alpha variant of the coronavirus was predominant.
It could not be determined whether the same protection also applies to the delta variant, which is most widespread in Denmark today.
It also did not provide efficacy data on COVID-19-related deaths or hospital admissions as none occurred after the combined vaccination program.
Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price, meaning that prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this information.
Fusion Media or any other person involved in Fusion Media assumes no liability for any loss or damage that may arise from reliance on the information contained on this website, including data, prices, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment.